

an Extension of Time for Three Months, to and including January 3, 2003; (2) a Notice of Appeal, both including the required fees; and (3) a Supplemental Information Disclosure Statement.

IN THE CLAIMS:

Please amend the claims pursuant to 37 C.F.R. 1.121 as follows (see the accompanying "marked up" version pursuant to 1.121):

J 1. (Amended) A method for reducing a level of amyloid- β (A β) peptides *in vivo*, which method comprises administering an A β level reducing dose of an estrogen compound to an animal, wherein the animal has an increased level of A β , and wherein the dose of the estrogen compound does not affect soluble APP levels.

J 20. (Twice Amended) A method for delaying or reducing the likelihood of, or ameliorating, a disease or disorder associated with amyloidosis, which method comprises administering an A β level reducing dose of an estrogen compound to a subject who has an increased risk for developing or shows a symptom of the disease or disorder associated with amyloidosis, wherein the dose of the estrogen compound does not affect soluble APP levels.

Please add the following new claims:

31. The method according to claim 4, wherein the dose of conjugated equine estrogen is selected from the group consisting of 0.3 mg, 0.625 mg, 1.25 mg, and 2.5 mg.

32. The method according to claim 20, wherein the estrogen compound is a conjugated equine estrogen.

33. The method according to claim 32, wherein the dose of conjugated equine estrogen is selected from the group consisting of 0.3 mg, 0.625 mg, 1.25mg, and 2.5 mg.

REMARKS

This submission is in response to the Official Action dated July 3, 2002 and the telephonic interview held on September 24, 2002. The undersigned and Dr. F. Shoarinejad thank the Examiner for the courtesy of the telephonic interview.

Claims 1-33 are pending in the application. Claims 1-30 stand rejected. Claims 1 and 20 have been amended. Support for the amendment to claim 1 and 20 can be found in the specification as filed at page 6, line 29, and at page 7, lines 15-16. New claims 31-33 are supported at page 19, lines 6-9. No new matter has been introduced by the amendments.